Medicine Mexicor
Pharmacotherapeutic group
Cardiac drugs. Other cardiac drugs.
ATX code C01E B
Content
Active substance: 1 capsule contains 100 mg of ethyl methylhydroxypyridine succinate in 100%;
Excipients: potato starch, povidone, lactose monohydrate, magnesium stearate, microcrystalline cellulose;
capsule shell: titanium dioxide (E 171), gelatin, sunset yellow dye (E 110), quinoline yellow dye (E 104).
Medicinal form
Capsules
Main physicochemical properties
Yellow hard gelatin capsules No. 2. The contents of the capsules aregranules, which contain granules and powder of white and white with a yellowish tint.
Indications
Complex therapy of coronary heart disease; complex therapy of ischemic stroke; dyscirculatory encephalopathy; mild and moderate cognitive disorders of various genesis.
Contraindications
Increased individual sensitivity to the drug, liver or kidney failure, pregnancy or breastfeeding, children’s age.
Method of administration and dosage
Mexicor is taken orally. Therapeutic doses and duration of treatment are determined by the doctor depending on the nosological form of the disease and the patient’s sensitivity to the drug. Treatment begins with a dose of 100 mg 3 times a day, gradually increasing the dose until a therapeutic effect is obtained. The maximum daily dose should not exceed 800 mg, a single dose should not exceed 200 mg. It is advisable to divide the daily dose of the drug into 3 doses during the day. The duration of the course of therapy with Mexicor in patients with coronary heart disease and cerebral circulation disorders is at least 1.5‒2 months. Repeated courses of therapy on the recommendation of a doctor should preferably be carried out in the spring and autumn periods. In the complex therapy of dyscirculatory encephalopathy, mild and moderate cognitive disorders, the drug is prescribed in a dose of 100 mg 3-4 times a day. The duration of treatment is determined by the doctor depending on the course of the disease and the patient’s condition. Course therapy with Mexicor should be completed gradually, reducing the daily dose of the drug by 100 mg.
For more detailed information, read the patient information leaflet